{
    "nctId": "NCT01991340",
    "briefTitle": "H.E.R.O.S. Study: An Observational Study of the Cardiac Safety of Herceptin (Trastuzumab) in Patients With HER2-Positive Breast Cancer",
    "officialTitle": "H.E.R.O.S. Study: Observational Study to Assess the Cardiac Safety Profile of Trastuzumab in Patients With HER2-positive Breast Cancer.",
    "overallStatus": "COMPLETED",
    "conditions": "Breast Cancer",
    "studyType": "OBSERVATIONAL",
    "phase": "N/A",
    "allocation": "N/A",
    "primaryPurpose": "N/A",
    "enrollmentCount": 657,
    "primaryOutcomeMeasure": "Safety: Incidence of adverse events",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Adult patients, \\>/= 18 years of age\n* Histologically confirmed HER2-positive breast cancer\n* Eligible to receive Herceptin as per Summary of Product Characteristics\n\nExclusion Criteria:\n\n* Contra-indications according to Summary of Product Characteristics",
    "sex": "ALL",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}